(Total Views: 451)
Posted On: 06/01/2019 9:12:00 PM
Post# of 36566
NSABP FB-14
A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic-Triple-Negative Breast Cancer
Protocol Chair: Leisha A. Emens, MD, PhD
Protocol Officer: Samuel Jacobs, MD
Primary Objective: To establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer.
Patient Population: Metastatic triple-negative breast cancer
Target Accrual: 29 patients
Status: Recruiting participants
ClinicalTrials.gov Identifier:
- See more at: https://www.nsabp.org/NSABP-Research/Industry...5vLFr.dpuf
A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic-Triple-Negative Breast Cancer
Protocol Chair: Leisha A. Emens, MD, PhD
Protocol Officer: Samuel Jacobs, MD
Primary Objective: To establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer.
Patient Population: Metastatic triple-negative breast cancer
Target Accrual: 29 patients
Status: Recruiting participants
ClinicalTrials.gov Identifier:
- See more at: https://www.nsabp.org/NSABP-Research/Industry...5vLFr.dpuf
(3)
(0)
